In this issue, Steven J Hoffman & John-Arne Røttingen (854–864) assess options for a global research and development agreement. In related editorials, Benn McGrady (794) weighs the legal implications of choices made by Member States, Carlos M Correa (795) details the potential features of a new model for pharmaceutical research and James Love (796) discusses different possibilities for its scope.